Skip to main content

Research Repository

Advanced Search

Assessment of Cannabidiol and ?9-Tetrahydrocannabiol in Mouse Models of Medulloblastoma and Ependymoma

Andradas, Clara; Byrne, Jacob; Kuchibhotla, Mani; Ancliffe, Mathew; Jones, Anya C; Carline, Brooke; Hii, Hilary; Truong, Alexandra; Storer, Lisa C D; Ritzmann, Timothy A; Grundy, Richard G; Gottardo, Nicholas G; Endersby, Raelene

Assessment of Cannabidiol and ?9-Tetrahydrocannabiol in Mouse Models of Medulloblastoma and Ependymoma Thumbnail


Authors

Clara Andradas

Jacob Byrne

Mani Kuchibhotla

Mathew Ancliffe

Anya C Jones

Brooke Carline

Hilary Hii

Alexandra Truong

Lisa C D Storer

RICHARD GRUNDY richard.grundy@nottingham.ac.uk
Professor of Paediatric Neuro-Oncology

Nicholas G Gottardo

Raelene Endersby



Abstract

Children with medulloblastoma and ependymoma are treated with a multidisciplinary approach that incorporates surgery, radiotherapy, and chemotherapy; however, overall survival rates for patients with high-risk disease remain unsatisfactory. Data indicate that plant-derived cannabinoids are effective against adult glioblastoma; however, preclinical evidence supporting their use in pediatric brain cancers is lacking. Here we investigated the potential role for ?9- tetrahydrocannabinol (THC) and cannabidiol (CBD) in medulloblastoma and ependymoma. Dose- dependent cytotoxicity of medulloblastoma and ependymoma cells was induced by THC and CBD in vitro, and a synergistic reduction in viability was observed when both drugs were combined. Mechanistically, cannabinoids induced cell cycle arrest, in part by the production of reactive oxygen species, autophagy, and apoptosis; however, this did not translate to increased survival in orthotopic transplant models despite being well tolerated. We also tested the combination of cannabinoids with the medulloblastoma drug cyclophosphamide, and despite some in vitro synergism, no survival advantage was observed in vivo. Consequently, clinical benefit from the use of cannabinoids in the treatment of high-grade medulloblastoma and ependymoma is expected to be limited. This study emphasizes the importance of preclinical models in validating therapeutic agent efficacy prior to clinical trials, ensuring that enrolled patients are afforded the most promising therapies available.

Citation

Andradas, C., Byrne, J., Kuchibhotla, M., Ancliffe, M., Jones, A. C., Carline, B., …Endersby, R. (2021). Assessment of Cannabidiol and ∆9-Tetrahydrocannabiol in Mouse Models of Medulloblastoma and Ependymoma. Cancers, 13, Article 330. https://doi.org/10.3390/cancers13020330

Journal Article Type Article
Acceptance Date Jan 15, 2021
Online Publication Date Jan 18, 2021
Publication Date Jan 2, 2021
Deposit Date Jan 18, 2021
Publicly Available Date Feb 12, 2021
Journal Cancers
Publisher MDPI
Peer Reviewed Peer Reviewed
Volume 13
Article Number 330
DOI https://doi.org/10.3390/cancers13020330
Public URL https://nottingham-repository.worktribe.com/output/5242552